相关临床试验
19
12 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1997
进行中（未招募）
4
21.1%
已完成
5
26.3%
尚未招募
8
42.1%
招募中
2
10.5%
暂无批准数据
- The BioE3 Policy, approved in August 2024, has catalyzed over 270 funded projects across six thematic sectors including precision biotherapeutics, bio-based chemicals, and climate-resilient agriculture. - Seventeen biofoundry and biomanufacturing hub facilities have received funding, while 15 Bio-AI Hubs have been recommended to accelerate AI-driven biological design and translational research. - A BioE3-Strain Resource Centre has been established in Pune to provide indigenous microbial strains with freedom-to-operate, supporting the Make-in-India initiative and reducing reliance on imported technologies. - The GenomeIndia project has sequenced over 10,000 Indian genomes and identified nearly 180 million genetic variants, creating a foundation for AI/ML-driven precision medicine applications.
- Centivax has initiated Phase 1a first-in-human trials of Centi-Flu 01, a universal flu vaccine designed to protect against all influenza strains including seasonal, pandemic, and future variants. - The vaccine uses epitope-focusing technology to target conserved viral regions that cannot mutate, aiming to provide broader protection than current seasonal vaccines which are often less than 50% effective. - The Phase 1 program will enroll approximately 300 healthy volunteers across multiple hemispheres and evaluate safety and immunogenicity against a panel of 24 flu strains using established correlates of protection. - Centivax has secured over $26 million in non-dilutive funding from organizations including the Gates Foundation, CEPI, and NIH, with the universal flu vaccine addressing a $7 billion global market.
- PharmaJet is developing a suite of proprietary needle-free self-injection pens for subcutaneous delivery of chronic disease treatments and metabolic peptides, currently in early testing phases. - The company's existing Tropis intradermal system has demonstrated superior user acceptance with over 95% caregiver preference and significant reductions in patient-reported pain and soreness compared to traditional needle injections. - Clinical evidence shows needle-free delivery can improve patient compliance rates, with PharmaJet's technology having been used for over 12 million vaccine injections worldwide. - The new pen injectors will incorporate smart e-technology for dose tracking and aim to address needle aversion barriers that impact treatment compliance in chronic disease management.
- Centivax raised an oversubscribed $45 million Series A round led by Future Ventures to advance its universal flu vaccine through Phase I clinical trials beginning within eight months. - The company's epitope-focusing platform technology demonstrated universal immunity against all tested influenza viruses in preclinical studies across multiple animal models and human immune organoids. - Former Pfizer and Merck vaccine executive Dr. Emilio Emini joined the board of directors, bringing extensive experience in vaccine development including contributions to Prevnar. - The Phase I trial will test the vaccine's efficacy against over twenty flu strains using the gold-standard hemagglutination inhibition assay in direct comparison with existing seasonal flu vaccines.
• Deerfield Management has secured more than $600 million for its third innovation fund, focusing on investments in drugs, medical devices, and healthcare services. • The new fund will operate from Deerfield's "Cure" campus in New York City and leverage partnerships with nearly 30 academic institutions to nurture healthcare startups. • With over $15 billion in assets under management, Deerfield's investment strategy comes amid a shift in biotech venture funding toward larger, more selective "megarounds" exceeding $100 million.
- Dyadic International reported $3.5 million in total revenue for 2024, including approximately $1.9 million in milestone and license revenue, demonstrating significant progress in commercializing its proprietary protein production platforms. - The company secured up to $7.5 million in grants from CEPI and the Gates Foundation to accelerate its C1 platform development for manufacturing vaccines and antibodies faster at lower costs. - Multiple products are approaching market launch, including Human Serum Albumin and DNASe1, while the company continues to expand its alternative protein portfolio and advance developments in animal and human health applications.
- Micron Biomedical has secured $43 million in total grant funding, including a recent $7.5 million grant from the Bill & Melinda Gates Foundation to support measles-rubella vaccine development and manufacturing scale-up. - The company's innovative dissolvable microarray technology allows painless, needle-free delivery of vaccines through the skin, potentially eliminating cold chain requirements and enabling administration by non-clinicians. - Recent clinical trials published in The Lancet demonstrated the technology safely immunized children as young as 9 months against measles and rubella, with the company now preparing for the world's first Phase 2 trial of needle-free vaccine technology in infants.
- Insud Pharma receives $2.7 million from the Bill & Melinda Gates Foundation to advance a sublingual oxytocin formulation for preventing postpartum hemorrhage (PPH). - The Phase II clinical trial will determine the optimal dose of the thermostable sublingual oxytocin, which doesn't require refrigeration or skilled personnel for administration. - The collaboration aims to reduce maternal mortality, particularly in low- and middle-income countries where PPH is a leading cause of death, affecting approximately 14 million women annually. - Mundo Sano Foundation will support awareness campaigns and facilitate access to the treatment in underserved regions, promoting equitable healthcare access.
- Six tuberculosis vaccine candidates are currently undergoing Phase 3 clinical trials, marking a crucial step towards combating the disease and antimicrobial resistance. - The M72/AS01E (M72) vaccine candidate, backed by the Bill & Melinda Gates Foundation and Wellcome, has garnered significant attention and entered Phase 3 testing this year. - The M72 Phase 3 trial aims to enroll approximately 20,000 participants, including individuals infected with TB, to assess the vaccine's efficacy and safety. - New TB vaccines are considered crucial for controlling the disease, especially in light of increasing antimicrobial resistance and its disproportionate impact on deprived populations.
- NIAID-supported clinical trial demonstrates that an HIV vaccine candidate can elicit broadly neutralizing antibodies (bNAbs) targeting the membrane proximal external region (MPER) of HIV, a crucial step toward developing an effective preventive vaccine. - The vaccine generated immune responses in 13 out of 20 recipients, with two participants showing antibodies capable of neutralizing multiple HIV strains after receiving three doses, occurring within weeks rather than years. - Complementary animal studies using nanoparticle-based immunogens successfully stimulated precursor B cells that could develop into cells producing 10E8-class bNAbs, which target a highly conserved region of HIV's surface protein gp41.
